CN118141097A - A kind of policosanol nano preparation and preparation method thereof - Google Patents
A kind of policosanol nano preparation and preparation method thereof Download PDFInfo
- Publication number
- CN118141097A CN118141097A CN202410266658.0A CN202410266658A CN118141097A CN 118141097 A CN118141097 A CN 118141097A CN 202410266658 A CN202410266658 A CN 202410266658A CN 118141097 A CN118141097 A CN 118141097A
- Authority
- CN
- China
- Prior art keywords
- polycosanol
- policosanol
- ethanol
- preparation
- preparing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
- A23L29/045—Organic compounds containing nitrogen as heteroatom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/10—Foods or foodstuffs containing additives; Preparation or treatment thereof containing emulsifiers
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y40/00—Manufacture or treatment of nanostructures
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nanotechnology (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Crystallography & Structural Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Mycology (AREA)
- Manufacturing & Machinery (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
Abstract
本发明提供了一种普利醇纳米制剂及其制备方法,属于普利醇制备技术领域。本发明首先制备蛋白质溶液,然后将普利醇、乳化剂及乙醇混合,制备普利醇溶液;将上述两种溶液混合加入乳化稳定剂混合,去除乙醇,经过冷冻干燥,得到普利醇纳米制剂。本发明所述的普利醇纳米制剂具有良好的包埋率、溶解性和分散性,能够有效提高普利醇的水溶性。The present invention provides a policosanol nanoformulation and a preparation method thereof, and belongs to the technical field of policosanol preparation. The present invention first prepares a protein solution, then mixes policosanol, an emulsifier and ethanol to prepare a policosanol solution; the two solutions are mixed and an emulsifier stabilizer is added to mix, the ethanol is removed, and the policosanol nanoformulation is obtained through freeze drying. The policosanol nanoformulation of the present invention has good embedding rate, solubility and dispersibility, and can effectively improve the water solubility of policosanol.
Description
技术领域Technical Field
本发明涉及普利醇制备技术领域,尤其涉及一种普利醇纳米制剂及其制备方法。The invention relates to the technical field of policosanol preparation, and in particular to a policosanol nano preparation and a preparation method thereof.
背景技术Background technique
普利醇是天然存在的高级醇,主要成分为二十八烷醇,外观为白色粉末或鳞片状晶体,可溶于有机溶剂,不溶于水,主要存在于蔗蜡、米糠蜡、小麦胚芽油、蜂蜡及虫蜡等天然产物中。多项研究表明普利醇具有增强耐力、抗疲劳、降血脂、抗炎、护肝等独特的生理功能,但是因其水溶性差,生物利用率低,使得普利醇在食品或药品中的应用受到限制。Policosanol is a naturally occurring higher alcohol, the main component of which is octacosanol. It appears as white powder or flaky crystals, is soluble in organic solvents but insoluble in water, and is mainly found in natural products such as cane wax, rice bran wax, wheat germ oil, beeswax, and insect wax. Many studies have shown that policosanol has unique physiological functions such as enhancing endurance, resisting fatigue, lowering blood lipids, resisting inflammation, and protecting the liver. However, due to its poor water solubility and low bioavailability, the application of policosanol in food or medicine is limited.
发明内容Summary of the invention
为解决普利醇的水溶性差的问题,本发明的目的是提供一种普利醇纳米制剂的制备方法,本发明制备的普利醇纳米制剂具有良好的包埋率、溶解性和分散性,能够有效提高普利醇的水溶性。In order to solve the problem of poor water solubility of policosanol, the purpose of the present invention is to provide a method for preparing a policosanol nanoformulation. The policosan nanoformulation prepared by the present invention has good embedding rate, solubility and dispersibility, and can effectively improve the water solubility of policosanol.
本发明中一种普利醇纳米制剂的制备方法,包括如下步骤:A method for preparing a policosanol nanoformulation in the present invention comprises the following steps:
(1)将蛋白质分散溶解于去离子水中,然后经过水化,得到蛋白质溶液;(1) dispersing and dissolving the protein in deionized water, and then hydrating the solution to obtain a protein solution;
(2)将普利醇与乳化剂加入到乙醇中,然后水浴搅拌溶解均匀,得到普利醇溶液;(2) adding policosanol and an emulsifier into ethanol, and then stirring in a water bath to dissolve uniformly to obtain a policosanol solution;
(3)在搅拌状态下将步骤(1)所述蛋白质溶液与步骤(2)所述普利醇溶液混合,并在搅拌状态下加入乳化稳定剂混合均匀,然后经过均质处理和微射流处理,得到混合乳液;(3) mixing the protein solution of step (1) and the policosanol solution of step (2) under stirring, adding an emulsion stabilizer under stirring and mixing them evenly, and then subjecting the mixture to homogenization and microfluidization to obtain a mixed emulsion;
(4)将步骤(3)所述混合乳液中的乙醇去除,得到去除乙醇的混合乳液,然后将去除乙醇的混合乳液经过冷冻干燥,得到普利醇纳米制剂。(4) removing ethanol from the mixed emulsion in step (3) to obtain a mixed emulsion from which ethanol has been removed, and then freeze-drying the mixed emulsion from which ethanol has been removed to obtain a policosanol nanoformulation.
进一步地,步骤(1)所述蛋白质为卵转铁蛋白。Furthermore, the protein in step (1) is ovotransferrin.
进一步地,步骤(1)所述蛋白质溶液中,蛋白质与去离子水的质量体积比为1~3mg/mL。Furthermore, in the protein solution of step (1), the mass volume ratio of protein to deionized water is 1 to 3 mg/mL.
进一步地,步骤(1)所述水化温度为0~10℃,水化时间为6~24h。Furthermore, the hydration temperature in step (1) is 0 to 10° C., and the hydration time is 6 to 24 hours.
进一步地,步骤(2)所述乳化剂为磷脂。Furthermore, the emulsifier in step (2) is phospholipid.
进一步地,步骤(2)所述普利醇和乳化剂的质量比为1:(1~5)。Furthermore, in step (2), the mass ratio of policosanol to emulsifier is 1:(1-5).
进一步地,步骤(2)所述乳化剂与乙醇的质量体积比为10~30mg/mL。Furthermore, in step (2), the mass volume ratio of the emulsifier to ethanol is 10 to 30 mg/mL.
进一步地,步骤(2)所述水浴搅拌温度为80~100℃,水浴搅拌时间为1~5min。Furthermore, in step (2), the water bath stirring temperature is 80-100° C., and the water bath stirring time is 1-5 min.
进一步地,步骤(3)所述乳化稳定剂为阿拉伯胶。Furthermore, the emulsion stabilizer in step (3) is gum arabic.
进一步地,步骤(3)所述乳化稳定剂与乳化剂的质量比为1:(1~5)。Furthermore, in step (3), the mass ratio of the emulsion stabilizer to the emulsifier is 1:(1-5).
进一步地,步骤(3)所述混合乳液中蛋白质溶液与普利醇溶液的体积比为10:(1~3)。Furthermore, the volume ratio of the protein solution to the policosanol solution in the mixed emulsion of step (3) is 10:(1-3).
进一步地,步骤(3)所述均质处理的转速为3000~10000rpm,均质处理的时间为3~8min。Furthermore, the rotation speed of the homogenization treatment in step (3) is 3000-10000 rpm, and the time of the homogenization treatment is 3-8 min.
进一步地,步骤(3)所述微射流处理的压力为30~90MPa,微射流处理的次数为1~5次。Furthermore, the pressure of the microfluidization treatment in step (3) is 30 to 90 MPa, and the number of microfluidization treatments is 1 to 5 times.
进一步地,步骤(4)所述将混合乳液中乙醇去除的方式为旋转蒸发;所述旋转蒸发的温度为40~50℃,旋转蒸发的真空度为0.04~0.1MPa。Furthermore, in step (4), the method of removing ethanol from the mixed emulsion is rotary evaporation; the temperature of the rotary evaporation is 40 to 50° C., and the vacuum degree of the rotary evaporation is 0.04 to 0.1 MPa.
进一步地,步骤(4)所述冷冻干燥前将去除乙醇的混合乳液用去离子水稀释至旋转蒸发前的质量。Furthermore, before freeze-drying in step (4), the mixed emulsion from which ethanol has been removed is diluted with deionized water to a mass before rotary evaporation.
进一步地,步骤(4)所述冷冻干燥的时间为24~48h。Furthermore, the freeze-drying time in step (4) is 24 to 48 hours.
本发明的另一目的是提供一种通过上述制备方法制得的普利醇纳米制剂。Another object of the present invention is to provide a policosanol nanoformulation prepared by the above preparation method.
与现有技术相比,本发明具有以下有益效果:Compared with the prior art, the present invention has the following beneficial effects:
本发明选用卵转铁蛋白是一种蛋白质,具有成膜性,在本发明中作为壁材使用对其他物质具有包埋效果,且卵转铁蛋白具有较好的界面活性,可作为一种天然的乳化剂提升对普利醇的乳化效果,从而减小普利醇纳米制剂的粒径。同时,卵转铁蛋白还具有抗氧化、抗菌、抗肿瘤和抗炎等多种生物学特性。因此,本发明所采用的卵转铁蛋白不但能够提高普利醇的水溶性和生物利用率,并且具有多种生物学特性,有利于扩展普利醇在食品药品当中的应用。The present invention selects ovotransferrin, which is a protein with film-forming property. It is used as a wall material in the present invention to have an embedding effect on other substances. In addition, ovotransferrin has good interfacial activity and can be used as a natural emulsifier to improve the emulsification effect on policosanol, thereby reducing the particle size of the policosanol nanoformulation. At the same time, ovotransferrin also has multiple biological properties such as anti-oxidation, antibacterial, anti-tumor and anti-inflammatory. Therefore, the ovotransferrin used in the present invention can not only improve the water solubility and bioavailability of policosanol, but also has multiple biological properties, which is conducive to expanding the application of policosanol in food and medicine.
具体实施方式Detailed ways
下面结合实施例对本发明作进一步说明。The present invention will be further described below in conjunction with the embodiments.
实施例1Example 1
一种普利醇纳米制剂的制备方法,步骤如下:A method for preparing a policosanol nanoparticle preparation comprises the following steps:
(1)按照卵转铁蛋白与去离子水的质量体积比为2mg/mL,常温及磁力搅拌条件下,将卵转铁蛋白分散溶解于去离子水中,然后将其置于4℃冰箱中充分水化12h,得到蛋白质溶液;(1) dispersing and dissolving ovotransferrin in deionized water at a mass volume ratio of ovotransferrin to deionized water of 2 mg/mL at room temperature and under magnetic stirring, and then placing the solution in a refrigerator at 4° C. for full hydration for 12 h to obtain a protein solution;
(2)按照普利醇与磷脂的质量比为1:2,磷脂与乙醇的质量体积比为15mg/mL,将普利醇与磷脂加入到乙醇中,在95℃水浴加热、磁力搅拌条件下充分溶解2min,得到普利醇溶液;(2) adding policosanol and phospholipids to ethanol at a mass ratio of 1:2 and a mass volume ratio of phospholipids to ethanol of 15 mg/mL, and fully dissolving them in a 95° C. water bath with magnetic stirring for 2 min to obtain a policosanol solution;
(3)按照蛋白质溶液与普利醇溶液的体积比为5:1将普利醇溶液加入到蛋白质溶液中,并按照阿拉伯胶与磷脂的质量比为1:5在搅拌状态下加入阿拉伯胶混合均匀,之后在转速为5000rpm的条件下进行均质处理,均质处理的时间为5min,然后在压力为80MPa的条件下进行微射流处理,微射流处理的次数为2次,得到混合乳液;(3) adding the policosanol solution to the protein solution at a volume ratio of 5:1, adding gum arabic to the phospholipid at a mass ratio of 1:5 under stirring and mixing, then homogenizing at a rotation speed of 5000 rpm for 5 min, and then microfluidizing at a pressure of 80 MPa for 2 times to obtain a mixed emulsion;
(4)将步骤(3)得到的混合乳液置于蒸馏瓶中,在温度为45℃、真空度为0.09MPa的条件下进行旋转蒸发去除乙醇,将旋转蒸发去除乙醇的混合乳液用去离子水稀释至旋转蒸发前的质量,然后进行冷冻干燥,冷冻干燥时间为24h,得到普利醇纳米制剂。(4) placing the mixed emulsion obtained in step (3) in a distillation flask, and performing rotary evaporation to remove ethanol at a temperature of 45° C. and a vacuum degree of 0.09 MPa, diluting the mixed emulsion from which ethanol has been removed by rotary evaporation with deionized water to the mass before rotary evaporation, and then freeze-drying the mixed emulsion for 24 hours to obtain a policosanol nanoformulation.
实施例2Example 2
一种普利醇纳米制剂的制备方法,包括如下步骤:A method for preparing a policosanol nanoformulation comprises the following steps:
(1)按照卵转铁蛋白与去离子水的质量体积比为2mg/mL,常温及磁力搅拌条件下,将卵转铁蛋白分散溶解于去离子水中,然后将其置于4℃冰箱中充分水化12h,得到蛋白质溶液;(1) dispersing and dissolving ovotransferrin in deionized water at a mass volume ratio of ovotransferrin to deionized water of 2 mg/mL at room temperature and under magnetic stirring, and then placing the solution in a refrigerator at 4° C. for full hydration for 12 h to obtain a protein solution;
(2)按照普利醇与磷脂的质量比为1:3,磷脂与乙醇的质量体积比为20mg/mL,将普利醇与磷脂加入到乙醇中,在95℃水浴加热、磁力搅拌条件下充分溶解2min,得到普利醇溶液;(2) adding policosanol and phospholipids to ethanol at a mass ratio of 1:3 and a mass volume ratio of phospholipids to ethanol of 20 mg/mL, and fully dissolving them in a 95° C. water bath with magnetic stirring for 2 min to obtain a policosanol solution;
(3)按照蛋白质溶液与普利醇溶液的体积比为5:1将普利醇溶液加入到蛋白质溶液中,并按照阿拉伯胶与磷脂的质量比为1:5在搅拌状态下加入阿拉伯胶混合均匀,之后在转速为5000rpm的条件下进行均质处理,均质处理的时间为5min,然后在压力为80MPa的条件下进行微射流处理,微射流处理的次数为2次,得到混合乳液;(3) adding the policosanol solution to the protein solution at a volume ratio of 5:1, adding gum arabic to the phospholipid at a mass ratio of 1:5 under stirring and mixing, then homogenizing at a rotation speed of 5000 rpm for 5 min, and then microfluidizing at a pressure of 80 MPa for 2 times to obtain a mixed emulsion;
(4)将步骤(3)得到的混合乳液置于蒸馏瓶中,在温度为45℃、真空度为0.09MPa的条件下进行旋转蒸发去除乙醇,将旋转蒸发去除乙醇的混合乳液用去离子水稀释至旋转蒸发前的质量,然后进行冷冻干燥,冷冻干燥时间为24h,得到普利醇纳米制剂。(4) placing the mixed emulsion obtained in step (3) in a distillation flask, and performing rotary evaporation to remove ethanol at a temperature of 45° C. and a vacuum degree of 0.09 MPa, diluting the mixed emulsion from which ethanol has been removed by rotary evaporation with deionized water to the mass before rotary evaporation, and then freeze-drying the mixed emulsion for 24 hours to obtain a policosanol nanoformulation.
实施例3Example 3
一种普利醇纳米制剂的制备方法,包括如下步骤:A method for preparing a policosanol nanoformulation comprises the following steps:
(1)按照卵转铁蛋白与去离子水的质量体积比为3mg/mL,常温及磁力搅拌条件下,将卵转铁蛋白分散溶解于去离子水中,然后将其置于4℃冰箱中充分水化12h,得到蛋白质溶液;(1) dispersing and dissolving ovotransferrin in deionized water at a mass volume ratio of ovotransferrin to deionized water of 3 mg/mL at room temperature and under magnetic stirring, and then placing the solution in a refrigerator at 4° C. for 12 hours to obtain a protein solution;
(2)按照普利醇与磷脂的质量比为1:3,磷脂与乙醇的质量体积比为20mg/mL,将普利醇与磷脂加入到乙醇中,在95℃水浴加热、磁力搅拌条件下充分溶解2min,得到普利醇溶液;(2) adding policosanol and phospholipids to ethanol at a mass ratio of 1:3 and a mass volume ratio of phospholipids to ethanol of 20 mg/mL, and fully dissolving them in a 95° C. water bath with magnetic stirring for 2 min to obtain a policosanol solution;
(3)按照蛋白质溶液与普利醇溶液的体积比为5:1将普利醇溶液加入到蛋白质溶液中,并按照阿拉伯胶与磷脂的质量比为1:5在搅拌状态下加入阿拉伯胶混合均匀,之后在转速为5000rpm的条件下进行均质处理,均质处理的时间为5min,然后在压力为80MPa的条件下进行微射流处理,微射流处理的次数为2次,得到混合乳液;(3) adding the policosanol solution to the protein solution at a volume ratio of 5:1, adding gum arabic to the phospholipid at a mass ratio of 1:5 under stirring and mixing, then homogenizing at a rotation speed of 5000 rpm for 5 min, and then microfluidizing at a pressure of 80 MPa for 2 times to obtain a mixed emulsion;
(4)将步骤(3)得到的混合乳液置于蒸馏瓶中,在温度为45℃、真空度为0.09MPa的条件下进行旋转蒸发去除乙醇,将旋转蒸发去除乙醇的混合乳液用去离子水稀释至旋转蒸发前的质量,然后进行冷冻干燥,冷冻干燥时间为24h,得到普利醇纳米制剂。(4) placing the mixed emulsion obtained in step (3) in a distillation flask, and performing rotary evaporation to remove ethanol at a temperature of 45° C. and a vacuum degree of 0.09 MPa, diluting the mixed emulsion from which ethanol has been removed by rotary evaporation with deionized water to the mass before rotary evaporation, and then freeze-drying the mixed emulsion for 24 hours to obtain a policosanol nanoformulation.
对比例1Comparative Example 1
对比例1将实施例3中的卵转铁蛋白替换成大豆分离蛋白,其余步骤与实施例3相同。Comparative Example 1: In Comparative Example 1, the ovotransferrin in Example 3 was replaced with soy protein isolate, and the remaining steps were the same as those in Example 3.
对实施例1~3及对比例1制备的普利醇纳米制剂进行包埋率、粒径、Zeta电位和PDI的检测。其中,The embedding efficiency, particle size, Zeta potential and PDI of the policosan nanoparticles prepared in Examples 1 to 3 and Comparative Example 1 were tested.
包埋率:采用气相色谱法测定制得的普利醇纳米制剂的包埋率:Embedding rate: The embedding rate of the prepared policosanol nanoformulation was determined by gas chromatography:
包埋率=(1-表面普利醇的量/总普利醇的量)×100%Embedding rate = (1-surface policosan amount/total policosan amount) × 100%
粒径、Zeta电位和PDI:利用粒度电位仪测定制得的普利醇纳米制剂的粒径、Zeta电位和PDI。Particle size, Zeta potential and PDI: The particle size, Zeta potential and PDI of the prepared policosanol nanoformulation were measured using a particle size potential analyzer.
实验结果如表1。The experimental results are shown in Table 1.
表1Table 1
以上数据表明,实施例1~3制得的普利醇纳米制剂具有良好的包埋率、复溶性(复溶的粒径)和分散性(PDI),可有效地提高普利醇的水溶性。The above data show that the policosanol nanoformulations prepared in Examples 1 to 3 have good embedding rate, redissolubility (redissolved particle size) and dispersibility (PDI), and can effectively improve the water solubility of policosanol.
以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims (10)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410266658.0A CN118141097A (en) | 2024-03-08 | 2024-03-08 | A kind of policosanol nano preparation and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410266658.0A CN118141097A (en) | 2024-03-08 | 2024-03-08 | A kind of policosanol nano preparation and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118141097A true CN118141097A (en) | 2024-06-07 |
Family
ID=91297734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410266658.0A Pending CN118141097A (en) | 2024-03-08 | 2024-03-08 | A kind of policosanol nano preparation and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN118141097A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030232796A1 (en) * | 2002-06-10 | 2003-12-18 | Elan Pharma International, Ltd. | Nanoparticulate polycosanol formulations & novel polycosanol combinations |
| US20110059181A1 (en) * | 2009-08-11 | 2011-03-10 | Nanopax Pharma, Llc | Methods for drug delivery comprising unfolding and folding proteins and peptide nanoparticles |
| US20120045482A1 (en) * | 2010-08-23 | 2012-02-23 | NanoRx, Inc. | Policosanol nanoparticles |
| CN112999158A (en) * | 2021-03-03 | 2021-06-22 | 江西省科学院生物资源研究所 | Preparation method and application of policosanol nano-liposome |
-
2024
- 2024-03-08 CN CN202410266658.0A patent/CN118141097A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030232796A1 (en) * | 2002-06-10 | 2003-12-18 | Elan Pharma International, Ltd. | Nanoparticulate polycosanol formulations & novel polycosanol combinations |
| US20110059181A1 (en) * | 2009-08-11 | 2011-03-10 | Nanopax Pharma, Llc | Methods for drug delivery comprising unfolding and folding proteins and peptide nanoparticles |
| US20120045482A1 (en) * | 2010-08-23 | 2012-02-23 | NanoRx, Inc. | Policosanol nanoparticles |
| CN112999158A (en) * | 2021-03-03 | 2021-06-22 | 江西省科学院生物资源研究所 | Preparation method and application of policosanol nano-liposome |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105286011B (en) | A kind of soluble soybean polysaccharide-soybean protein-curcumin complex and preparation and application | |
| CN108634169B (en) | A kind of preparation method of lutein nanoemulsion | |
| CN102614127B (en) | Resveratrol nanoscale dispersoid and preparation method thereof | |
| KR101363757B1 (en) | Double layered capsule for cosmetics and method of manufacturing the same | |
| Yuan et al. | pH-driven self-assembly of alcohol-free curcumin-loaded propylene glycol alginate nanoparticles | |
| CN113796533A (en) | Pickering nano emulsion with stable soybean protein particles and loaded lutein ester and preparation method thereof | |
| Chen et al. | Food emulsifier based on the interaction of casein and butyrylated dextrin for improving stability and emulsifying properties | |
| Ma et al. | Fabrication of emulsions using high loaded curcumin nanosuspension stabilizers: Enhancement of antioxidant activity and concentration of curcumin in micelles | |
| WO2022073439A1 (en) | Nano-selenium pickering emulsion, preparation method therefor, and applications thereof | |
| CN110192651A (en) | A kind of preparation method of the nanoemulsions using soybean protein isolate load phytosterin ester | |
| CN113317508A (en) | Water-soluble phytosterol nanoparticles and preparation method thereof | |
| Li et al. | Fabrication of nanoemulsion stabilized by high-pressure modified soy protein isolate-genistein for the encapsulation of lutein | |
| CN115381775B (en) | Fishskin gelatin emulsion stabilized by luteolin and preparation method and application thereof | |
| CN118141097A (en) | A kind of policosanol nano preparation and preparation method thereof | |
| CN119837779A (en) | Glabridin nano vesicle based on glycyrrhizic acid encapsulation, preparation method thereof and application thereof in preparation of whitening and skin care cosmetics | |
| CN108283621B (en) | Nasal cavity nano preparation mometasone furoate liquid crystal gel nanoparticle and preparation method thereof | |
| CN118121502B (en) | Ergothioneine composition embedding delivery preparation and preparation method and application thereof | |
| CN117982345B (en) | Colloidal sulfur anti-inflammatory antibacterial agent and preparation method and application thereof | |
| CN117398293B (en) | Preparation method and application of liposome for wrapping soothing and repairing components by using micro-jet homogenizer | |
| Karim et al. | Encapsulation of Lutein Within Ultrasonicated Peach Gum-Sodium Caseinate Complex Nanoparticles Via Electrostatic Complexation: Physiochemical Properties, Structural Interaction Mechanisms, and In Vitro Release Analyses | |
| CN118141106A (en) | A plant sterol nano preparation and its preparation method and application | |
| CN113854576B (en) | Preparation method of sodium caseinate-pectin-phytosterol nanoparticles | |
| Yan et al. | Effects of different surfactants on the conjugates of soybean protein-polyphenols for the preparation of β-carotene microcapsules | |
| CN115553465A (en) | Method for preparing beta-carotene loaded oil-in-water emulsion | |
| CN116983214A (en) | Liposome for cosmetics and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |